Royal Bank of Canada
IMUC

Royal Bank of Canada’s ImmunoCellular Therapeutics, Ltd. IMUC Stock Holding History

Royal Bank of Canada’s Portfolio IMUC Stock Details IMUC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-13
Closed -$1K – 6430
2014
Q2 		$1K Buy
+13
New +$627 ﹤0.01% 5887

Other funds holding IMUC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CC
Callan Capital La Jolla, California $1.35B AUM 8.35% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Royal Bank of Canada's IMUC Position: Q3 2014 in Review

Royal Bank of Canada sold out of ImmunoCellular Therapeutics, Ltd. (IMUC) in Q3 2014, closing a stake of 13 shares — an estimated $1K sold.

Royal Bank of Canada first reported a position in IMUC in Q2 2014 and held it in 1 quarter. The position peaked at $1K in Q2 2014. 39 funds tracked by Wall St. Rank hold IMUC as of Q3 2014.

  • Royal Bank of Canada reported no remaining ImmunoCellular Therapeutics, Ltd. position as of Q3 2014 after selling out during the quarter.
  • Royal Bank of Canada sold 13 ImmunoCellular Therapeutics, Ltd. shares in Q3 2014, an estimated $1K.
  • Royal Bank of Canada first reported a position in ImmunoCellular Therapeutics, Ltd. in Q2 2014 and held it in 1 quarter.
  • Royal Bank of Canada's ImmunoCellular Therapeutics, Ltd. position peaked at $1K in Q2 2014.
  • 39 funds tracked by Wall St. Rank held ImmunoCellular Therapeutics, Ltd. as of Q3 2014.

Based on Royal Bank of Canada's 13F filing for Q3 2014, filed 14 Nov 2014.